Photodynamic Therapy Efficacy of the Human Papillomavirus-Related Cervical Lesions

Read full text
Authors: Alexander Dushkin, Т. Г. Гришачева, S. S. Afanasiev, Irina Dushkina, Alexander Karaulov, Biryukova Elena, Akmaral Khangeldi, Kristina Babayan, Nasrula Shanazarov, M. S. Afanasiev
Cited by: 2
References: 18

Abstract

Background/Objectives: This study aims to fill certain knowledge gaps by assessing the clinical effectiveness of PDT in a large group of women with HPV-related cervical lesions and examining how different patient factors affect treatment results. Methods: A total of 811 women aged from 19 to 76 were retrospectively analyzed who were treated by PDT of HPV infection with atypical squamous cells and HPV-related cervical lesions. PDT was performed using chlorin e6-based systemic photosensitizers. Irradiation was carried out at 662 nm. The endocervical dose was 334 J/cm2, and the ectocervical dose was 291 J/cm2. Results: Overall HPV clearance was 91.1%, lesion remission was 95.3%, and complete response was 88.3%, with the highest complete response observed in the HSIL group compared with HPV-positive ASCs. Multivariable models showed that multiple HPV infection (especially >3 genotypes) and pregnancy history were associated with lower odds of complete response, while younger age (18–25 years) and TZ2 were associated with higher odds of complete response. Conclusions: PDT using chlorin e6-based photosensitizers demonstrated high clinical and virological effectiveness across HPV-related cervical abnormalities, including HSIL, supporting its role as an organ-preserving treatment option. Multiple HPV genotypes and pregnancy history may identify patients at increased risk of partial response and warrant closer follow-up or tailored treatment strategies.

Fields of Study & Subjects

Photodynamic Therapy Research Studies Head and Neck Cancer Studies Skin Protection and Aging

Publication details

Journal / source
Journal of Clinical Medicine
Publisher
MDPI AG
Volume
15
Issue
4
Pages
1596–1596
Publication date
19 February 2026
Language
EN